Literature DB >> 16610049

Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.

Cheng-Zhi Qiu1, Chuan Wang, Zhong-Xin Huang, Shi-Ze Zhu, You-Yi Wu, Jian-Long Qiu.   

Abstract

AIM: To study the SSTR1, 2, 3, 4, 5 expression and their relationships with clinico-pathological factors, cell proliferation, Bcl-2 and p53 expression in colorectal cancer cells.
METHODS: Immunohistochemical staining of five SSTR subtypes, Ki-67, Bcl-2 and p53 was performed by the standard streptavidin-peroxidase (SP) technique for the paraffin sections of 127 colorectal cancers. and expression of five SSTR subtypes in 40 specimens of normal colorectal mucosae was detected with the same method.
RESULTS: Positive staining for five SSTR subtypes was observed in colorectal cancer cells and normal colorectal mucosae. SSTR1 was the most predominant subtype in both colorectal cancer and normal colorectal mucosa, and the second was SSTR5 or SSTR2. As compared with normal colorectal mucosa, SSTR4 was more frequently expressed in colorectal cancer cells (2.5% vs 18.9%, P<0.05); the expression of SSTR2, 4, 5 in moderately to well differentiated colorectal adenocarcinoma was significantly higher than that in poorly differentiated ones (P<0.05), the SSTR1 expression in colorectal cancer with positive lymph node metastasis was significantly higher than that with negative lymph node metastasis (72.2% and 54.5%,P<0.05). In addition, in the ulcerative type of colorectal cancer, SSTR2 expression was obviously decreased (P<0.05); the correlation did not reach a statistical significance between the five SSTR subtypes expression and Dukes'stages (P>0.05), but the frequency of SSTR1 expression increased with Dukes'stage, while SSTR3 and SSTR5 expression decreased with Dukes' stage. Moreover, there was no correlation between expression of the five SSTR subtypes and other clinicopathological factors such as age, sex, tumor site, tumor depth, distant metastasis. The proliferative indexes in colorectal cancer cells with negative expression of SSTR2 and SSTR3 were significantly higher than that with positive expression (P<0.05). The Bcl-2 expression in colorectal cancer cells with positive expression of SSTR1, 2, 3, 5 was significantly lower than that with negative expression (P<0.05). There was no correlation between five SSTR subtypes and p53 expression.
CONCLUSION: The most predominant SSTR subtype is SSTR1, and the second is SSTR2 or SSTR5. Five SSTR subtypes play different roles in the development of colorectal cancer. SSTR2 and SSTR3 can inhibit the proliferation and promote apoptosis of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610049      PMCID: PMC4087677          DOI: 10.3748/wjg.v12.i13.2011

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  Antiproliferative effect of somatostatin and analogs.

Authors:  C Bousquet; E Puente; L Buscail; N Vaysse; C Susini
Journal:  Chemotherapy       Date:  2001       Impact factor: 2.544

2.  Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer.

Authors:  P Rochaix; N Delesque; J P Estève; N Saint-Laurent; J J Voight; N Vaysse; C Susini; L Buscail
Journal:  Hum Gene Ther       Date:  1999-04-10       Impact factor: 5.695

3.  The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src.

Authors:  A Steták; A Lankenau; T Vántus; P Csermely; A Ullrich; G Kéri
Journal:  Biochem Biophys Res Commun       Date:  2001-07-13       Impact factor: 3.575

4.  Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma.

Authors:  V Vuaroqueaux; A Dutour; N Bourhim; L Ouafik; G Monges; N Briard; N Sauze; C Oliver; M Grino
Journal:  J Mol Endocrinol       Date:  2000-06       Impact factor: 5.098

5.  Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models.

Authors:  Fabienne Vernejoul; Patrick Faure; Naoual Benali; Denis Calise; Gérard Tiraby; Lucien Pradayrol; Christiane Susini; Louis Buscail
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

6.  Modulation of potassium current and calcium influx by somatostatin in rod bipolar cells isolated from the rabbit retina via sst2 receptors.

Authors:  C Petrucci; V Resta; F Fieni; A Bigiani; P Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-06       Impact factor: 3.000

7.  Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Eur J Nucl Med       Date:  2001-07

8.  Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.

Authors:  Claudia Casini Raggi; Antonino Calabrò; Daniela Renzi; Vittorio Briganti; Fabio Cianchi; Luca Messerini; Rosa Valanzano; Michela Cameron Smith; Camillo Cortesini; Francesco Tonelli; Mario Serio; Mario Maggi; Claudio Orlando
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

9.  Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts.

Authors:  Zhi-Yong Du; Ren-Yi Qin; Wei Xia; Rui Tian; Manoj Kumar
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

Review 10.  The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

Authors:  M Hejna; M Schmidinger; M Raderer
Journal:  Ann Oncol       Date:  2002-05       Impact factor: 32.976

View more
  17 in total

1.  Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.

Authors:  Guisheng Zhou; Shi-He Liu; Kelly M Shahi; Hua Wang; Xueyan Duan; Xia Lin; Xin-Hua Feng; Min Li; William E Fisher; Francesco J Demayo; David Dawson; F Charles Brunicardi
Journal:  Mol Endocrinol       Date:  2012-06-05

2.  Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

Authors:  R Colucci; C Blandizzi; N Ghisu; T Florio; M Del Tacca
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes.

Authors:  Guisheng Zhou; Marie-Claude Gingras; Shi-He Liu; Robbi Sanchez; Dean Edwards; David Dawson; Kurt Christensen; Giovanni Paganelli; Richard Gibbs; William Fisher; Francis C Brunicardi
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

5.  Upregulated Expression of SSTR3 is Involved in Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats.

Authors:  Qi Yao; Qianqian Liu; Hui Xu; Zhonghua Wu; Liang Zhou; Zhikai Gu; Peipei Gong; Jianhong Shen
Journal:  Cell Mol Neurobiol       Date:  2017-02-07       Impact factor: 5.046

6.  The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function.

Authors:  Guisheng Zhou; Marie-Claude Gingras; Shi-He Liu; Donghui Li; Zhijun Li; Robbi L Catania; Kelly M Stehling; Min Li; Giovanni Paganelli; Richard A Gibbs; Francesco J Demayo; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

7.  Upregulated expression of SSTR1 is involved in neuronal apoptosis and is coupled to the reduction of bcl-2 following intracerebral hemorrhage in adult rats.

Authors:  Damin Yuan; Jianhong Shen; Yaohua Yan; Xinmin Wu; Aihong Li; Aisong Guo; Yuanyuan Wu; Chengwei Duan; Jiabing Shen; Cuiying Tang; Dongmei Zhang; Yuhong Ji
Journal:  Cell Mol Neurobiol       Date:  2014-07-18       Impact factor: 5.046

8.  Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Ying-Lin Yang; Jian Wu; He Huang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

9.  Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer.

Authors:  Jonathan M Lehman; Megan D Hoeksema; Jeremy Staub; Jun Qian; Bradford Harris; J Clay Callison; Jennifer Miao; Chanjuan Shi; Rosana Eisenberg; Heidi Chen; Sheau-Chiann Chen; Pierre P Massion
Journal:  Int J Cancer       Date:  2018-10-09       Impact factor: 7.396

10.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.